Understanding Outcomes for Life-Threatening Neurologic Illness
This observational study aims to better understand life-threatening brain illnesses like intracerebral hemorrhage (bleeding in the brain) and status epilepticus (prolonged seizures). Researchers are looking at how these conditions affect the brain and how standard medical care might impact recovery. They are collecting information from patients admitted to the NeuroCritical Care Unit to see how different factors, including complications like fever or infections, influence long-term outcomes. Success in this study will be measured by how well participants recover their daily living skills, thinking abilities, and overall independence three months after their illness. This study is currently unclear on its recruitment status.
- Study design
- This is an observational study, meaning researchers are collecting information without providing any specific intervention. It plans to include up to 5000 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants' recovery is assessed at three months after their illness.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Improving Outcomes for Patients With Life-Threatening Neurologic Illness
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Gunjan Y Parikh, MD · PRINCIPAL_INVESTIGATOR · University of Maryland, Baltimore
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Number of participants who score great than 60 on the Barthel Index3 month
The Barthel scale is an ordinal scale used to measure performance in activities of daily living. Scores range from 0 to 100. A higher score signifies better outcomes, more independent functionality.
- Number of participants who score great than 26 on the Montreal Cognitive Assessment (MoCA)3 month
The Montreal Cognitive Assessment was developed as a quick screening tool for neurological function. It assesses the domains of attention and concentration, executive function, memory, language, visuoconstructional skills, conceptual thinking, calculation, and orientation. The MoCA has been tested extensively for use in a variety of disorders affecting cognition such as HIV, Huntington's chorea, Multiple Sclerosis, Parkinson's disease, stroke, vascular dementia, and substance abuse in addition to the wellness of older adults. The MoCA has been tested in ages ranging from as young as 49 in two reports to old-old (85+) with a variety of education levels. The total possible score is 30 points with a score of 26 or more considered normal.
- Number of participants who score 1 or less on the Modified Rankin Scale3 month
The Modified Rankin Scale (mRS) measures degree of disability/dependence after a stroke. Scores range from 0 to 6. A lower score signifies better outcomes, more independent functionality.
- Number of participants who have experienced adverse events3 month
Medical history from hospital discharge to three months will help researchers learn of any adverse events or other medical complications.
- Number of participants who score great than 75 on the EuroQOL3 month
EQ-5D is a standardised measure of health status developed by the EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal. The EQ-5D questionnaire also includes a Visual Analog Scale (VAS), by which respondents can report their perceived health status with a grade ranging from 0 (the worst possible health status) to 100 (the best possible health status).